Editas Medicine to present LNP research at ESGCT congress in October

Editas Medicine, Inc. (Nasdaq: EDIT) will present two posters at the European Society of Gene and Cell Therapy 33rd Annual Congress, scheduled for Oct. 27-30, 2026, in Hamburg, Germany, according to a company statement.

Both presentations are scheduled for Oct. 28, 2026, during Poster Session 1, from 1:30 to 3:30 p.m. CET, and will be delivered by Harry An, Director of Process Development at Editas Medicine.

The first poster, abstract number P0361, is titled "Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletion." The second poster, abstract number P0781, is titled "Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeutics."

Editas Medicine management is also scheduled to participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on Nov. 10, 2026, at 2:30 p.m. ET in Boston, Massachusetts.

You May Also Be Interested In

• Comfort Systems USA CFO to retire in 2027, successor named
• Carnival Corp. (CCL) Declares $0.15 Quarterly Dividend; 2.2% Yield
• Integra Resources reports Q3 gold output of 17,652 oz at Florida Canyon